Figure 1
Figure 2
Figure 3
Comparison of post-embolization syndrome
| Adverse events | DEB-TACE (n = 45) | cTACE (n = 45) | P value |
|---|---|---|---|
| Fatigue (n/%) | 5 (11.1) | 7 (15.6) | 0.535 |
| Fever (n/%) | 23 (51.1) | 13 (28.9) | 0.031 |
| Abdominal (n/%) distension | 9 (20) | 7 (15.6) | 0.581 |
| Abdominal pain (n/%) Numeric Rating Scale (NRS) | 42 (93.3) 4.4 ± 1.9 | 43 (95.6) 3.6 ± 1.6 | 0.645 0.037 |
| Nausea/emesis (n/%) | 10 (22.2) | 12 (26.7) | 0.624 |
Comparison of treatment response evaluated at 1-month, 3-month, and 6-month after treatment between the two groups
| Parameters | 1-month | 3-month | 6-month | ||||||
|---|---|---|---|---|---|---|---|---|---|
| DEB-TACE group (n = 45) | cTACE group (n = 45) | P value | DEB-TACE group (n = 45) | cTACE group (n = 45) | P value | DEB-TACE group (n = 44) | cTACE group (n = 45) | P value | |
| CR (%) | 8 (17.8) | 6 (13.3) | 0.561 | 10 (22.2) | 3 (6.7) | 0.036 | 7 (15.9) | 3 (6.7) | 0.168 |
| PR (%) | 24 (53.3) | 16 (35.6) | 0.090 | 23 (51.1) | 16 (35.6) | 0.137 | 23 (52.3) | 13 (28.9) | 0.025 |
| ORR (%) | 32 (71.1) | 22 (48.9) | 0.031 | 33 (73.3) | 19 (42.2) | 0.003 | 30 (68.2) | 16 (35.6) | 0.002 |
| SD (%) | 10 (22.2) | 18 (40.0) | 0.069 | 6 (13.3) | 11 (24.4) | 0.178 | 10 (22.7) | 17 (37.8) | 0.123 |
| DCR (%) | 42 (93.3) | 40 (88.9) | 0.459 | 39 (86.7) | 30 (66.7) | 0.025 | 40 (90.9) | 33 (73.3) | 0.031 |
| PD (%) | 3 (6.7) | 5 (11.1) | 0.459 | 6 (13.3) | 15 (33.3) | 0.025 | 4 (9.1) | 12 (26.7) | 0.031 |
Baseline characteristics of patients
| Parameters | DEB-TACE(n = 45) | (cTACE n = 45) | P value |
|---|---|---|---|
| Gender (male/female) | 40/5 | 39/6 | 0.747 |
| Age (years) | 58.9 ± 7.1 | 60.6 ± 6.5 | 0.229 |
| History (n/%) of alcohol consumption | 11 (24.4) | 15 (33.3) | 0.352 |
| History of viral hepatitis (n/%) | 31 (68.9) | 27 (60.0) | 0.378 |
| Child-Pugh stage (n/%) | |||
| A | 33 (73.3) | 29 (64.4) | 0.326 |
| B | 12 (26.7) | 16 (35.6) | - |
| BCLC stage (n/%) | |||
| A | 17 (37.8) | 14 (31.1) | 0.506 |
| B | 28 (62.2) | 31 (68.9) | - |
| ECOG performance status (n/%) | |||
| 0 | 17 (37.8) | 13 (28.9) | 0.371 |
| 1 | 28 (62.2) | 32 (71.1) | - |
| Liver function | |||
| ALT (U/L) | 38.0 ± 20.5 | 35.7 ± 18.7 | 0.585 |
| AST (U/L) | 40.3 ± 16.8 | 40.1 ± 14.2 | 0.946 |
| ALB (g/L) | 39.9 ± 8.2 | 40.1 ± 6.2 | 0.886 |
| TBIL (μmol/L) | 19.1 ± 6.1 | 20.7 ± 7.0 | 0.246 |
| Tumour location (n/%) | |||
| Unilobar | 35 (77.8) | 32 (71.1) | 0.468 |
| Bilobar | 10 (22.2) | 13 (28.9) | - |
| Tumour distribution (n/%) | |||
| Unifocal | 36 (80.0) | 34 (75.6) | |
| Multifocal | 9 (20.0) | 11 (24.4) | 0.612 |
| Diameter of the largest tumour (cm) | 7.2 ± 2.4 | 6.8 ± 2.3 | 0.397 |
Compared with the baseline, the changes of liver function at 1-week and 1-month after procedure in the two groups
| Parameters | DEB-TACE (n = 45) | cTACE (n = 45) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | 1-week | P value | 1-month | P value | Baseline | 1-week | P value | 1-month | P value | |
| ALT (U/L) | 38.0 ± 20.5 | 65.0 ± 18.3 | < 0.001 | 35.3 ± 19.8 | 0.431 | 35.7 ± 18.7 | 55.2 ± 19.8 | <0.001 | 37.4 ± 13.5 | 0.558 |
| AST (U/L) | 40.3 ± 16.8 | 61.3 ± 19.7 | < 0.001 | 39.1 ± 12.2 | 0.722 | 40.1 ± 14.2 | 52.4 ± 20.0 | 0.003 | 38.2 ± 11.7 | 0.534 |
| ALB (g/L) | 39.9 ± 8.2 | 36.7 ± 5.5 | 0.004 | 40.3 ± 7.21 | 0.758 | 40.1 ± 6.2 | 37.2 ± 5.4 | 0.027 | 39.1 ± 6.9 | 0.508 |
| TIBL (umol/L) | 19.1 ± 6.1 | 30.0 ± 10.2 | < 0.001 | 18.0 ± 5.2 | 0.399 | 20.7 ± 7.0 | 24.8 ± 10.4 | 0.003 | 19.0 ± 7.0 | 0.328 |